1st Quarter - Report

FRESENIUS MEDICAL CARE NORTH AMERICA for FRESENIUS MEDICAL CARE NORTH AMERICA

Firm
Client
Income
—
Expenses
$2,550,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Telehealth policies/CMS Waivers S. 3593- Telehealth Extension and Evaluation Act H.R.1332 - Telehealth Modernization Act Transitional Drug Add-on Payment Adjustment (TDAPA) Clinical Labor Cuts in the Center for Medicare and Medicaid Services CY2022 Physician Fee Schedule Dialysis supply chain issues Dialysis preparedness planning HHS Provider Relief Fund H.R. 4065- Chronic Kidney Disease Improvement in Research and Treatment Act Issues related to ESRD bundled payment system cuts in the FY22 Appropriations bill Legislation related to telehealth and dialysis centers Legislation related to Charitable Premium Assistance for ESRD patients

Foreign entity interest: Fresenius Medical Care AG and Co. KGaA is the sole indirect owner of Fresenius Medical Care Holdings, Inc. (dba Fresenius Medical Care North America) and has an interest in the issues lobbied.

LobbyistCovered position, as disclosed
CHRISTOPHER F BUKI —
STACEY FAHRNER —
LAURA KEMPER —
CAMERON LYNCH —
TALEEN MEKHDJAVAKIAN —

Contacted: HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); SENATE

Bills named: H.R. 1332 (117th), S. 3593 (117th), H.R. 4065 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.